Travere Therapeutics, Inc. (TVTX) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Improved cash flow ⢠High leverage TVTX shows strong liquidity and recent quarterly cash-flow improvement, but its high leverage, ongoing annual losses, and rich valuation keep the investment case risky.
Price Behavior
Key Price Behavior Insights: ⢠Breakout surge ⢠Support holding ⢠Extended momentum Support Level: $38.8 to $39.5 Resistance Level: $42.1 TVTX has a strong uptrend over the last month after a sharp breakout above the low $30s, but it is now stretched below the recent $42.13 high, making a pause or pullback likely before any fresh breakout.
Sentiment & News
Key News Insights: ⢠FDA approval ⢠FSGS expansion ⢠Insider selling TVTX surged after FDA full approval of FILSPARI for FSGS, strengthening its first-in-class rare kidney disease position and supporting a potential multi-year revenue re-rating despite some insider selling.
AI Summary
TVTX has evolved from a single-product launch story into a two-indication rare kidney disease platform after FSGS approval, but with the stock already rerated, the investment now hinges on whether management can convert high gross margins and improving cash flow into sustained prescription growth without letting SG&A, leverage, or dilution risk outrun revenue.
Description
Travere Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare diseases. Its marketed portfolio includes treatments for bile acid disorders and a drug for cystinuria, while its pipeline comprises a Phase III program for kidney diseases and an investigational enzyme-replacement candidate for classical homocystinuria. The company conducts partnered research with the NIH and patient organizations on rare genetic conditions, was renamed from Retrophin in 2020, and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | TVTX | Travere Therapeutics, Inc. | Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally. | Closed | -2.0% |